A multicenter comparison of MOG-IgG cell-based assays
- PMID: 30728305
- PMCID: PMC6511109
- DOI: 10.1212/WNL.0000000000007096
A multicenter comparison of MOG-IgG cell-based assays
Abstract
Objectives: To compares 3 different myelin oligodendrocyte glycoprotein-immunoglobulin G (IgG) cell-based assays (CBAs) from 3 international centers.
Methods: Serum samples from 394 patients were as follows: acute disseminated encephalomyelitis (28), seronegative neuromyelitis optica (27), optic neuritis (21 single, 2 relapsing), and longitudinally extensive (10 single, 3 recurrent). The control samples were from patients with multiple sclerosis (244), hypergammaglobulinemia (42), and other (17). Seropositivity was determined by visual observation on a fluorescence microscope (Euroimmun fixed CBA, Oxford live cell CBA) or flow cytometry (Mayo live cell fluorescence-activated cell sorting assay).
Results: Of 25 samples positive by any methodology, 21 were concordant on all 3 assays, 2 were positive at Oxford and Euroimmun, and 2 were positive only at Oxford. Euroimmun, Mayo, and Oxford results were as follows: clinical specificity 98.1%, 99.6%, and 100%; positive predictive values (PPVs) 82.1%, 95.5%, and 100%; and negative predictive values 79.0%, 78.8%, and 79.8%. Of 5 false-positives, 1 was positive at both Euroimmun and Mayo and 4 were positive at Euroimmun alone.
Conclusions: Overall, a high degree of agreement was observed across 3 different MOG-IgG CBAs. Both live cell-based methodologies had superior PPVs to the fixed cell assays, indicating that positive results in these assays are more reliable indicators of MOG autoimmune spectrum disorders.
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures
Comment in
-
Live-cell based assays are the gold standard for anti-MOG-Ab testing.Neurology. 2019 Mar 12;92(11):501-502. doi: 10.1212/WNL.0000000000007077. Epub 2019 Feb 6. Neurology. 2019. PMID: 30728306 No abstract available.
-
Reader response: A multicenter comparison of MOG-IgG cell-based assays.Neurology. 2020 Mar 17;94(11):501. doi: 10.1212/WNL.0000000000009100. Neurology. 2020. PMID: 32179642 No abstract available.
References
-
- Reindl M, Jarius S, Rostasy K, Berger T. Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr Opin Neurol 2017;30:295–301. - PubMed
-
- Jitprapaikulsan J, Chen JJ, Flanagan EP, et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis. Ophthalmology 2018;125:1628–1637. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources